HRS-4642 + SHR-9839

HRS-4642 + SHR-9839 is an investigational **combination therapy** consisting of **HRS-4642**, a highly selective, non-covalent small molecule inhibitor of the KRAS G12D mutant protein, and **SHR-9839**, an investigational compound (modality not publicly detailed) being developed for the treatment of advanced solid tumors harboring KRAS G12D mutations. HRS-4642 demonstrates robust preclinical and early clinical efficacy against KRAS G12D-mutant cancers, targeting a mutation that is prevalent and difficult to treat in solid tumors such as pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. This combination is currently being evaluated in Phase IB/II clinical trials to assess safety, tolerability, and preliminary efficacy (measured as objective response rate, progression-free survival, and disease control rate) in patients with advanced solid tumors, particularly those harboring the KRAS G12D mutation. The mechanism of action centers on direct inhibition of **KRAS G12D** signaling. Detailed molecular targets or modality for SHR-9839 have not been publicly specified[1][3][5][4].